Overview

A Study of HRS9531 Versus Semaglutide Once Weekly as Add-on Therapy to Metformin Monotherapy or in Combination With SGLT2 Inhibitors in Participants With Type 2 Diabetes

Status:
ACTIVE_NOT_RECRUITING

Trial end date:
2026-09-30

Target enrollment:

Participant gender:

Summary

The study is being conducted to evaluate the efficacy and safety of HRS9531 once weekly (QW) in subjects with type 2 diabetes mellitus not adequately controlled with metformin monotherapy or in combination with SGLT2 inhibitors compared to Semaglutide QW for 36 weeks and 52 weeks.

Phase:

PHASE3

Details

Lead Sponsor:

Fujian Shengdi Pharmaceutical Co., Ltd.

Treatments:

semaglutide